Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema

Phase 4

Completed

Conditions: Diabetic Retinopathy

Interventions: Drug: ranibizumab 0.5 mg

First Posted Date: 2015-02-19

Last Posted Date: 2019-01-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 135

Registration Number: NCT02366468

Locations: 🇩🇪
Novartis Investigative Site, Wurzburg, Germany

Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers

Phase 3

Completed

Conditions: Psoriasis

Interventions: Biological: Secukinumab
Biological: Placebo

First Posted Date: 2015-02-13

Last Posted Date: 2018-12-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 132

Registration Number: NCT02362789

Locations: 🇩🇪
Novartis Investigative Site, Stuttgart, Germany

Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues

Phase 3

Completed

Conditions: Acromegaly

Interventions: Drug: Pasireotide LAR

First Posted Date: 2015-02-03

Last Posted Date: 2019-12-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 123

Registration Number: NCT02354508

Locations: 🇬🇧
Novartis Investigative Site, Plymouth, United Kingdom

Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma

Phase 1

Completed

Conditions: Liposarcoma

Interventions: Drug: HDM201
Drug: LEE011

First Posted Date: 2015-01-21

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 74

Registration Number: NCT02343172

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With Everolimus

Phase 4

Completed

Conditions: Growth and Development

Interventions: Drug: Everolimus

First Posted Date: 2015-01-14

Last Posted Date: 2024-08-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 15

Registration Number: NCT02338609

Locations: 🇺🇸
Cinn Children Hosp Medical Center SC, Cincinnati, Ohio, United States
🇷🇺
Novartis Investigative Site, Moscow, Russian Federation
🇺🇸
University Of California LA SC, Los Angeles, California, United States

and more 2 locations

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

Phase 2

Completed

Conditions: ALK-positive Non-small Cell Lung Cancer

Interventions: Drug: Ceritinib

First Posted Date: 2015-01-13

Last Posted Date: 2020-04-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 156

Registration Number: NCT02336451

Locations: 🇺🇸
The Ohio State University Comprehensive Cancer Center Ohio State University, Columbus, Ohio, United States
🇺🇸
USC Kenneth Norris Comprehensive Cancer Center SC-3, Los Angeles, California, United States
🇺🇸
Dana Farber Cancer Institute SC-12, Boston, Massachusetts, United States

and more 6 locations

Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma

Phase 2

Terminated

Conditions: Asthma

Interventions: Drug: QGE031
Drug: Placebo

First Posted Date: 2015-01-13

Last Posted Date: 2017-08-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT02336425

Locations: 🇸🇰
Novartis Investigative Site, Zvolen, Slovakia

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

Phase 1

Terminated

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Capmatinib
Drug: Nazartinib

First Posted Date: 2015-01-12

Last Posted Date: 2023-06-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 177

Registration Number: NCT02335944

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan ROC, Taiwan
🇺🇸
Massachusetts General Hospital Mass General, Boston, Massachusetts, United States

PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod

Completed

Conditions: Relapsing Remitting Multiple Sclerosis

First Posted Date: 2015-01-12

Last Posted Date: 2019-04-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 114

Registration Number: NCT02335892

Locations: 🇬🇧
Novartis Investigative Site, Nottingham, United Kingdom

A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies

Phase 3

Completed

Conditions: Hereditary Periodic Fevers
Systemic Juvenile Idiopathic Arthritis

Interventions: Drug: canakinumab

First Posted Date: 2015-01-08

Last Posted Date: 2020-05-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT02334748

Locations: 🇫🇷
Novartis Investigative Site, Paris, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy